Literature DB >> 25739160

Views of nonmedical, health system professionals regarding the return of whole genome sequencing incidental findings.

Kimberly A Strong, Kaija L Zusevics, David P Bick, Regan Veith.   

Abstract

BACKGROUND: Use of genome sequencing in the clinic continues to increase. In addition to its potential to provide findings of clinical benefit, it also has the potential to identify findings unrelated to the indication for testing (incidental findings). Incidental findings are the subject of considerable debate, particularly following the publication of recommendations by the American College of Medical Genetics and Genomics. This debate involves how and which results should be returned as well as stakeholders' desires for such results. Part of the difficulty in determining best practice in relation to returning incidental findings is the dearth of empirical data available regarding laypersons' attitudes and desire for the sometimes controversial information.
METHODS: In an effort to contribute data on views regarding the return of incidental findings following genome sequencing in a clinical setting, a survey specifically designed around the various types of incidental findings that occur, ranging from clinically actionable to nonactionable, was administered to a nonmedical population of medical coders working at a medical school (N = 97). Almost all (98%) of the respondents were women, 80% had 6 or more years of experience as a medical coder, and about three-fourths (74%) of participants reported that they had children.
RESULTS: The group surveyed was considerably more interested in receiving all types of results for both themselves and their children than previously surveyed genetics professionals.
CONCLUSION: Results from this study offer a snapshot of opinions beyond those of the professional genetic community and demonstrate a striking difference between genetic professionals and a more lay population in terms of their attitudes and desires regarding the return of incidental findings. Additional research is needed to explain the nuances in the perspectives motivating these variations.

Entities:  

Mesh:

Year:  2014        PMID: 25739160

Source DB:  PubMed          Journal:  WMJ        ISSN: 1098-1861


  6 in total

1.  Experiences and lessons learned by genetic counselors in returning secondary genetic findings to patients.

Authors:  Carly Rost; Karin M Dent; Jeffrey Botkin; Erin Rothwell
Journal:  J Genet Couns       Date:  2020-05-26       Impact factor: 2.537

2.  In Different Voices: The Views of People with Disabilities about Return of Results from Precision Medicine Research.

Authors:  Maya Sabatello; Yuan Zhang; Ying Chen; Paul S Appelbaum
Journal:  Public Health Genomics       Date:  2020-04-15       Impact factor: 2.000

3.  Decisional conflict among adolescents and parents making decisions about genomic sequencing results.

Authors:  Preethi Raghuram Pillai; Cynthia A Prows; Lisa J Martin; Melanie F Myers
Journal:  Clin Genet       Date:  2019-12-02       Impact factor: 4.438

4.  Exploring neurologists' perspectives on the return of next generation sequencing results to their patients: a needed step in the development of guidelines.

Authors:  Thierry Hurlimann; Iris Jaitovich Groisman; Béatrice Godard
Journal:  BMC Med Ethics       Date:  2018-09-29       Impact factor: 2.652

5.  Secondary findings and carrier test frequencies in a large multiethnic sample.

Authors:  Tomasz Gambin; Shalini N Jhangiani; Jennifer E Below; Ian M Campbell; Wojciech Wiszniewski; Donna M Muzny; Jeffrey Staples; Alanna C Morrison; Matthew N Bainbridge; Samantha Penney; Amy L McGuire; Richard A Gibbs; James R Lupski; Eric Boerwinkle
Journal:  Genome Med       Date:  2015-06-13       Impact factor: 15.266

6.  Whether, when, how, and how much? General public's and cancer patients' views about the disclosure of genomic secondary findings.

Authors:  Jude Emmanuel Cléophat; Michel Dorval; Zaki El Haffaf; Jocelyne Chiquette; Stephanie Collins; Benjamin Malo; Vincent Fradet; Yann Joly; Hermann Nabi
Journal:  BMC Med Genomics       Date:  2021-06-26       Impact factor: 3.063

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.